Jose Carlos Flores-Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jose Carlos Flores-Gonzalez has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Maria Lechuga-Sancho
Servicio de Pediatría, Hospital Universitario Puerta del Mar, Cádiz, Spain
6 shared publications Ana Estalella-Mendoza
Pediatric Intensive Care Unit, Puerta del Mar University Hospital, Avda Ana de Viya 21, 11009, Cádiz, Spain
3 shared publicationsArturo Hernández-González
Pediatric Intensivist, Pediatric Intensive Care Unit, Puerta del Mar University Hospital, Cádiz, Spain
3 shared publicationsFernando Rubio-Quiñones
Pediatric Intensivist, Pediatric Intensive Care Unit, Puerta del Mar University Hospital, Cádiz, Spain
3 shared publicationsMónica Saldaña-Valderas
Clinical Farmacology Unit, Puerta del Mar University Hospital, Cadiz, Spain
3 shared publicationsPatricia Rodríguez-Campoy
Pediatric Intensive Care Unit, Puerta del Mar University Hospital, Avda Ana de Viya 21, 11009, Cádiz, Spain
3 shared publications
Latest Publications
- Open Access
- 5 January 2022
- Published by MDPI AG in Tomography
- Vol. 8 (1) , 142-157
Characterization of Cardiopulmonary Interactions and Exploring Their Prognostic Value in Acute Bronchiolitis: A Prospective Cardiopulmonary Ultrasound Study
We aimed to delineate cardiopulmonary interactions in acute bronchiolitis and to evaluate the capacity of a combined cardiopulmonary ultrasonography to predict the need for respiratory support. This was a prospective observational single-center study that includes infants 2, the length of stay hospitalization, the PICU stay and the duration of respiratory support were a secondary outcome. We enrolled 112 infants (median age 1 (0.5–3) months; 62% males) hospitalized with acute bronchiolitis. Increased values of the pulmonary variables (BROSJOD score, pCO2 and LUS) showed moderate correlations with NT-proBNP and all echocardiographic parameters indicative of pulmonary hypertension and myocardial dysfunction (Tei index). Up to 36 (32%) infants required respiratory support during the hospitalization. This group presented with higher lung ultrasound score (p < 0.001) and increased values of NT-proBNP (p < 0.001), the Tei index (p < 0.001) and pulmonary artery pressures (p < 0.001). All the analyzed respiratory and cardiac variables showed moderate-to-strong correlations with the LOS of hospitalization and the time of respiratory support. Lung ultrasound and echocardiography showed a moderate-to-strong predictive accuracy for the need of respiratory support in the ROC analysis, with the AUC varying from 0.74 to 0.87. Those cases of bronchiolitis with a worse pulmonary status presented with a more impaired cardiac status. Cardiopulmonary ultrasonography could be a useful tool to easily identify high-risk populations for complicated acute bronchiolitis hospitalization.
- 5 January 2022
- Published by MDPI AG in Tomography
- Vol. 8 (1) , 142-157
Open AccessCharacterization of Cardiopulmonary Interactions and Exploring Their Prognostic Value in Acute Bronchiolitis: A Prospective Cardiopulmonary Ultrasound Study
We aimed to delineate cardiopulmonary interactions in acute bronchiolitis and to evaluate the capacity of a combined cardiopulmonary ultrasonography to predict the need for respiratory support. This was a prospective observational single-center study that includes infants 2, the length of stay hospitalization, the PICU stay and the duration of respiratory support were a secondary outcome. We enrolled 112 infants (median age 1 (0.5–3) months; 62% males) hospitalized with acute bronchiolitis. Increased values of the pulmonary variables (BROSJOD score, pCO2 and LUS) showed moderate correlations with NT-proBNP and all echocardiographic parameters indicative of pulmonary hypertension and myocardial dysfunction (Tei index). Up to 36 (32%) infants required respiratory support during the hospitalization. This group presented with higher lung ultrasound score (p < 0.001) and increased values of NT-proBNP (p < 0.001), the Tei index (p < 0.001) and pulmonary artery pressures (p < 0.001). All the analyzed respiratory and cardiac variables showed moderate-to-strong correlations with the LOS of hospitalization and the time of respiratory support. Lung ultrasound and echocardiography showed a moderate-to-strong predictive accuracy for the need of respiratory support in the ROC analysis, with the AUC varying from 0.74 to 0.87. Those cases of bronchiolitis with a worse pulmonary status presented with a more impaired cardiac status. Cardiopulmonary ultrasonography could be a useful tool to easily identify high-risk populations for complicated acute bronchiolitis hospitalization.
- 1 March 2021
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 73 (1) , 15-21
Respiratory adverse events during upper digestive endoscopies in children under ketamine sedation
- 1 March 2021
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 73 (1) , 15-21
Respiratory adverse events during upper digestive endoscopies in children under ketamine sedation
- 27 November 2018
- Published by Springer Nature in Pediatric Drugs
- Vol. 21 (1) , 25-31
Topical Pharyngeal Lidocaine Reduces Respiratory Adverse Events During Upper Gastrointestinal Endoscopies Under Ketamine Sedation in Children
Upper gastrointestinal endoscopies (UGEs) performed under ketamine sedation may increase the risk of respiratory adverse events (RAEs) due to pharyngeal stimulation. Topical lidocaine prevents general anesthesia-induced laryngospasm.
- 27 November 2018
- Published by Springer Nature in Pediatric Drugs
- Vol. 21 (1) , 25-31
Topical Pharyngeal Lidocaine Reduces Respiratory Adverse Events During Upper Gastrointestinal Endoscopies Under Ketamine Sedation in Children
Upper gastrointestinal endoscopies (UGEs) performed under ketamine sedation may increase the risk of respiratory adverse events (RAEs) due to pharyngeal stimulation. Topical lidocaine prevents general anesthesia-induced laryngospasm.
- 27 May 2017
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 42 (5) , 653-655
Supraventricular tachycardia after withdrawal of prolonged dexmedetomidine infusion in a paediatric patient without heart disease
Summary What is known and objective Dexmedetomidine (DEX) has been reported to be safe in paediatric patients. Case description We present the case of a girl without heart disease admitted at our PICU due to an influenza A acute respiratory distress syndrome, who suffered a paroxysmal supraventricular tachycardia (PSVT) twelve hours after DEX progressive withdrawal was completed. What is new and Conclusion This is the first report of PSVT as an adverse reaction to DEX in a paediatric patient without heart disease.
- 27 May 2017
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 42 (5) , 653-655
Supraventricular tachycardia after withdrawal of prolonged dexmedetomidine infusion in a paediatric patient without heart disease
Summary What is known and objective Dexmedetomidine (DEX) has been reported to be safe in paediatric patients. Case description We present the case of a girl without heart disease admitted at our PICU due to an influenza A acute respiratory distress syndrome, who suffered a paroxysmal supraventricular tachycardia (PSVT) twelve hours after DEX progressive withdrawal was completed. What is new and Conclusion This is the first report of PSVT as an adverse reaction to DEX in a paediatric patient without heart disease.
- Open Access
- 22 March 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-7
Prospective Multicentre Study on the Epidemiology and Current Therapeutic Management of Severe Bronchiolitis in Spain
Objective. To determine the epidemiology and therapeutic management of patients with severe acute bronchiolitis (AB) admitted to paediatric intensive care units (PICUs) in Spain.Design. Descriptive, prospective, multicentre study.Setting. Sixteen Spanish PICUs.Patients. Patients with severe AB who required admission to any of the participating PICUs over 1 year.Interventions. Both epidemiological variables and medical treatment received were recorded.Results. A total of 262 patients were recruited; 143 were male (54.6%), with median age of 1 month (0–23). Median stay in the PICU was 7 days (1–46). Sixty patients (23%) received no nebuliser treatment, while the rest received a combination of inhalation therapies. One-quarter of patients (24.8%) received corticosteroids and 56.5% antibiotic therapy. High-flow oxygen therapy was used in 14.3% and noninvasive ventilation (NIV) was used in 75.6%. Endotracheal intubation was required in 24.4% of patients. Younger age, antibiotic therapy, and invasive mechanical ventilation (IMV) were risk factors that significantly increased the stay in the PICU.Conclusions. Spanish PICUs continue to routinely use nebulised bronchodilator treatment and corticosteroid therapy. Despite NIV being widely used in this condition, intubation was required in one-quarter of cases. Younger age, antibiotic therapy, and IMV were associated with a longer stay in the PICU.
- 22 March 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-7
Open AccessProspective Multicentre Study on the Epidemiology and Current Therapeutic Management of Severe Bronchiolitis in Spain
Objective. To determine the epidemiology and therapeutic management of patients with severe acute bronchiolitis (AB) admitted to paediatric intensive care units (PICUs) in Spain.Design. Descriptive, prospective, multicentre study.Setting. Sixteen Spanish PICUs.Patients. Patients with severe AB who required admission to any of the participating PICUs over 1 year.Interventions. Both epidemiological variables and medical treatment received were recorded.Results. A total of 262 patients were recruited; 143 were male (54.6%), with median age of 1 month (0–23). Median stay in the PICU was 7 days (1–46). Sixty patients (23%) received no nebuliser treatment, while the rest received a combination of inhalation therapies. One-quarter of patients (24.8%) received corticosteroids and 56.5% antibiotic therapy. High-flow oxygen therapy was used in 14.3% and noninvasive ventilation (NIV) was used in 75.6%. Endotracheal intubation was required in 24.4% of patients. Younger age, antibiotic therapy, and invasive mechanical ventilation (IMV) were risk factors that significantly increased the stay in the PICU.Conclusions. Spanish PICUs continue to routinely use nebulised bronchodilator treatment and corticosteroid therapy. Despite NIV being widely used in this condition, intubation was required in one-quarter of cases. Younger age, antibiotic therapy, and IMV were associated with a longer stay in the PICU.
- 25 January 2017
- Published by Springer Nature in Endocrine
- Vol. 55 (3) , 989-991
Thyroid hormone intoxication as a not yet described cause of J-wave syndrome in a pediatric patient
- 25 January 2017
- Published by Springer Nature in Endocrine
- Vol. 55 (3) , 989-991
Thyroid hormone intoxication as a not yet described cause of J-wave syndrome in a pediatric patient
- 1 September 2016
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 20 (5) , 758-760
Severe pneumonia by Mycoplasma as an adverse event of everolimus therapy in patients with tuberous sclerosis complex
- 1 September 2016
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 20 (5) , 758-760
Severe pneumonia by Mycoplasma as an adverse event of everolimus therapy in patients with tuberous sclerosis complex
- 1 January 2016
- Published by Elsevier in Revista Iberoamericana de Micologia
- Vol. 33 (1) , 48-50
Primer caso de infección fúngica invasora por Candida fabianii en un paciente pediátrico no neonatal
- 1 January 2016
- Published by Elsevier in Revista Iberoamericana de Micologia
- Vol. 33 (1) , 48-50
Primer caso de infección fúngica invasora por Candida fabianii en un paciente pediátrico no neonatal
- Open Access
- 17 November 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (11) , e0142847
Epinephrine Improves the Efficacy of Nebulized Hypertonic Saline in Moderate Bronchiolitis: A Randomised Clinical Trial
There is no evidence that the epinephrine-3% hypertonic saline combination is more effective than 3% hypertonic saline alone for treating infants hospitalized with acute bronchiolitis. We evaluated the efficacy of nebulized epinephrine in 3% hypertonic saline. We performed a randomized, double-blind, placebo-controlled clinical trial in 208 infants hospitalized with acute moderate bronchiolitis. Infants were randomly assigned to receive nebulized 3% hypertonic saline with either 3 mL of epinephrine or 3 mL of placebo, administered every four hours. The primary outcome measure was the length of hospital stay. A total of 185 infants were analyzed: 94 in the epinephrine plus 3% hypertonic saline group and 91 in the placebo plus 3% hypertonic saline group. Baseline demographic and clinical characteristics were similar in both groups. Length of hospital stay was significantly reduced in the epinephrine group as compared with the placebo group (3.94 ±1.88 days vs. 4.82 ±2.30 days, P = 0.011). Disease severity also decreased significantly earlier in the epinephrine group (P = 0.029 and P = 0.036 on days 3 and 5, respectively). In our setting, nebulized epinephrine in 3% hypertonic saline significantly shortens hospital stay in hospitalized infants with acute moderate bronchiolitis compared to 3% hypertonic saline alone, and improves the clinical scores of severity from the third day of treatment, but not before. EudraCT 2009-016042-57
- 17 November 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (11) , e0142847
Open AccessEpinephrine Improves the Efficacy of Nebulized Hypertonic Saline in Moderate Bronchiolitis: A Randomised Clinical Trial
There is no evidence that the epinephrine-3% hypertonic saline combination is more effective than 3% hypertonic saline alone for treating infants hospitalized with acute bronchiolitis. We evaluated the efficacy of nebulized epinephrine in 3% hypertonic saline. We performed a randomized, double-blind, placebo-controlled clinical trial in 208 infants hospitalized with acute moderate bronchiolitis. Infants were randomly assigned to receive nebulized 3% hypertonic saline with either 3 mL of epinephrine or 3 mL of placebo, administered every four hours. The primary outcome measure was the length of hospital stay. A total of 185 infants were analyzed: 94 in the epinephrine plus 3% hypertonic saline group and 91 in the placebo plus 3% hypertonic saline group. Baseline demographic and clinical characteristics were similar in both groups. Length of hospital stay was significantly reduced in the epinephrine group as compared with the placebo group (3.94 ±1.88 days vs. 4.82 ±2.30 days, P = 0.011). Disease severity also decreased significantly earlier in the epinephrine group (P = 0.029 and P = 0.036 on days 3 and 5, respectively). In our setting, nebulized epinephrine in 3% hypertonic saline significantly shortens hospital stay in hospitalized infants with acute moderate bronchiolitis compared to 3% hypertonic saline alone, and improves the clinical scores of severity from the third day of treatment, but not before. EudraCT 2009-016042-57
- 30 September 2011
- Published by Elsevier in Medicina Intensiva (English Edition)
- Vol. 35 (6) , 344-348
Infección nosocomial del tracto urinario en niños críticos
- 30 September 2011
- Published by Elsevier in Medicina Intensiva (English Edition)
- Vol. 35 (6) , 344-348
Infección nosocomial del tracto urinario en niños críticos